Product information and disease descriptionProduct descriptionProduct information
Special populations
3 evidence topics · 2 sources
Hepatic impairment: single-dose study
| Population or parameter | Quoted finding |
|---|---|
| Mild and moderate hepatic impairment | “did not significantly affect the PK of saroglitazar” |
| Severe hepatic impairment: exposure | “increased 3-fold” |
| Severe hepatic impairment: clearance | “61% lower” |
| Severe hepatic impairment: authors’ qualification | “may require close monitoring or dose adjustments” |
Cholestatic cirrhosis and renal impairment: moderate hepatic impairment in PBC cirrhosis
Cholestatic cirrhosis and renal impairment: single-dose pharmacokinetics in non-cirrhotic cholestatic liver disease and severe renal impairment
Pregnancy, lactation, and pediatric use
No evidence found.